Company Overview and News

 
ThromboGenics Business Update - H1 2018

2018-09-06 globenewswire
Following shareholders' approval at an EGM held on September 3, 2018, and effective as of September 10, 2018, ThromboGenics NV is changing its corporate name to Oxurion NV. The new name Oxurion is designed to better reflect the company's ambition to deliver best in class therapies for back of the eye disorders, following recent progress made with the company's innovative diabetic eye disease pipeline.
THR TBGNF

 
ThromboGenics becomes "Oxurion"

2018-09-03 globenewswire
Shareholders approve new name which better reflects the Company's ambition to deliver best in class therapies for back of the eye disorders
THR TBGNF

 
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)

2018-07-19 globenewswire
Study results confirm safety and tolerability of THR-317 for intra-ocular use, and show improvement in visual acuity for up to 90 days after last injection
THR TBGNF

 
ThromboGenics Plans Name Change to "Oxurion"

2018-06-27 globenewswire
To better reflect Company's activities and ambition to deliver best in class therapies for back of the eye disorders
THR TBGNF

 
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC

2018-06-21 globenewswire
Leuven, Belgium, 21 June 2018 - ThromboGenics NV (Euronext Brussels: THR), a biopharma company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease, announces its participation and support of the seventh annual Prevent Blindness Focus on Eye Health National Summit which takes place on July 18, 2018, at the National Press Club in Washington, DC.
THR TBGNF

 
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)

2018-05-25 globenewswire
Leuven, Belgium, 25 May 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it has successfully enrolled the first patient in a Phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898).
THR TBGNF

 
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018

2018-05-23 globenewswire
Leuven, Belgium, 23 May 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group (EASDec) Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland.
THR TBGNF

 
ThromboGenics Business Update - Q1 2018

2018-05-09 globenewswire
Positive Initial Topline Data from Phase 1/ 2a Clinical Study evaluating THR-317, anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)
THR TBGNF

 
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

2018-04-27 globenewswire
Leuven, Belgium, April 27 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it has successfully enrolled the first patient in a Phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis®, Novartis), for the treatment of DME (NCT03499223).
THR TBGNF

 
ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317, an anti-PlGF, for the Treatment of Diabetic Macular Edema (DME)

2018-04-04 globenewswire
30% of anti-VEGF treatment naïve patients had a 3 line or more (> or equal to 15 letters) gain in Best Corrected Visual Acuity (BVCA) after 3 monthly injections with THR-317 (8mg)
THR TBGNF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...